June 4, 2021Open Access

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

In this phase 2 trial, sotorasib therapy led to a durable clinical benefit without new safety signals in patients with previously treated KRAS p.G12C-mutated NSCLC. (Funded by Amgen and the National Institutes of Health; CodeBreaK100 ClinicalTrials.gov number, NCT03600883.).

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Skoulidis et al. (Fri,) studied this question.

synapsesocial.com/papers/69d96e6234ded318bb684332 https://doi.org/https://doi.org/10.1056/nejmoa2103695

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1NSCLC: An Update of Driver Mutations, Their Role in Pathogenesis and Clinical Significance.2015 · 52 citations
2Frequency and Distinctive Spectrum of <i>KRAS</i> Mutations in Never Smokers with Lung Adenocarcinoma2008 · 570 citations
3Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial2016 · 4,784 citations
4Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy2019 · 1,012 citations
5K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways2018 · 260 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo